Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.

Detailed description:

Arms:
arm 1: Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose. arm 2: Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.

Interventions: intervention 1: Placebo intervention 2: Dulaglutide intervention 3: Glimepiride
Intervention descriptions: intervention 1: Administered SQ intervention 2: Administered SQ intervention 3: Administered PO

Protocol document: